List of bibliographic references
Number of relevant bibliographic references: 28.
[0-20] [
0 - 20][
0 - 28][
20-27][
20-40]
| Ident. | Authors (with country if any) | Title |
|---|
| 000332 (2000) |
J P Larsen [Norvège] ; K. Karlsen ; E. Tandberg | Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study. |
| 000409 (2000) |
N. Gálvez-Jiménez [États-Unis] ; M R Hanson ; J. Cabral | Dopa-resistant parkinsonism, oculomotor disturbances, chorea, mirror movements, dyspraxia, and dementia: the expanding clinical spectrum of hypoparathyroidism. A case report. |
| 000411 (2000) |
D. Dressler [Allemagne] ; U. Zettl ; R. Benecke ; H. Bigalke | Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? |
| 000502 (2001) |
J E Ahlskog [États-Unis] ; M D Muenter | Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. |
| 000A55 (2003) |
Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Monica A. Burke ; Carol Jacques ; Joseph H. Friedman | Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. |
| 000B97 (2003) |
Yoshikuni Mizuno [Japon] ; Nobuo Yanagisawa ; Sadako Kuno ; Mitsutoshi Yamamoto ; Kazuko Hasegawa ; Hideki Origasa ; Hisayuki Kowa | Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. |
| 000D74 (2004) |
Kai Wohlfarth [Allemagne] ; Knut Kampe ; Hans Bigalke | Pharmacokinetic properties of different formulations of botulinum neurotoxin type A. |
| 001022 (2005) |
Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Michael S. Okun | Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. |
| 001495 (1992) |
P. Genton ; R. Guerrini | Effect of alcohol on action myoclonus in Lance-Adams syndrome and progressive myoclonus epilepsy. |
| 001518 (2006) |
Richard Dubinsky [États-Unis] ; Carolyn Gray | CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. |
| 001822 (2006) |
Samay Jain [États-Unis] ; Paul E. Greene ; Steven J. Frucht | Tetrabenazine therapy of pediatric hyperkinetic movement disorders. |
| 001871 (2006) |
Joseph H. Friedman [États-Unis] ; Robert M. Berman ; Christopher G. Goetz ; Stewart A. Factor ; William G. Ondo ; Joanne Wojcieszek ; William H. Carson ; Ronald N. Marcus | Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. |
| 001946 (2007) |
| Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. |
| 001973 (2007) |
Christopher Kenney [États-Unis] ; Christine Hunter ; Joseph Jankovic [États-Unis] | Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. |
| 001B12 (2007) |
Carlos Singer [États-Unis] ; Janice Lamb ; Amanda Ellis ; Gary Layton | A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. |
| 001B34 (2007) |
Mayumi Kitagawa [Japon] ; Hideki Houzen ; Kunio Tashiro | Effects of caffeine on the freezing of gait in Parkinson's disease. |
| 001B84 (2007) |
Björn Holmberg [Suède] ; Jan-Ove Johansson ; Werner Poewe [Autriche] ; Gregor Wenning ; Niall P. Quinn ; Chris Mathias ; Eduardo Tolosa ; Adriana Cardozo ; Nil Dizdar ; Olivier Rascol ; Tarik Slaoui | Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. |
| 001C35 (2007) |
Günther Deuschl [Allemagne] ; Antanas Vaitkus ; Gabriele-Cornelia Fox ; Torsten Roscher ; Dieter Schremmer ; Ariel Gordin | Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. |
| 002B07 (2010) |
Stephen Gancher ; John Nutt | Tolerance to apomorphine develops and reverses rapidly. |
| 003C78 (1990) |
J. Vaamonde [Espagne] ; M R Luquin ; J A Obeso | Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. |
| 004176 (2015) |
Adriana Prundean [France] ; Katia Youssov ; Sandrine Humbert ; Dominique Bonneau ; Christophe Verny | A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Drug Tolerance"
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i \
-Sk "Drug Tolerance" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= indexItem
|index= Mesh.i
|clé= Drug Tolerance
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
